The online version of this article (doi:10.1186/s12876-017-0604-y) contains supplementary material, which is available to authorized users.
Efficacy of maintenance therapy in ulcerative colitis (UC) in the remission stage has been reported to depend on release profile or dosing regimen of oral 5-aminosalicylic acid (5-ASA) products used. Aim of this study is to investigate real life results in using oral 5-ASA products for maintaining mild to moderate UC patients in Japan.
Adult UC outpatients treated with oral 5-ASA products were enrolled from 379 sites in Japan between July 2012 and July 2013, and followed for 52 weeks. Remission maintenance rate was evaluated by products and dosages. Factors affecting recurrence were also examined.
A total of 5695 UC patients were registered. Among the 4677 patients in whom remission maintenance was observed, remission maintenance rate at week 52 was 80.2%. As for disease duration and dosage, Pentasa® 4000 mg/day in 2 divided doses was administered to 480 (21.0%) patients in remission and 341 (46.6%) patients in active stage, and Asacol® 3600 mg/day in 3 divided doses was administered to 696 (46.4%) patients in remission and 473 (67.3%) patients in active stage.
The remission maintenance rate at week 52 by dosage and frequency did not significantly differ between Pentasa® Tablets at 4000 mg/day in 2 divided doses (76.5%) and Asacol® Tablets at 3600 mg/day in 3 divided doses (76.1%, P = 0.7868).
Factors affecting the risk of relapse in UC were identified. Significantly persistent remission maintenance was noted in patients in whom duration of remission maintenance until enrollment was 12 to <24 months or ≥24 months relative to the reference category of <3 months (12 to <24 months: HR 0.600 [0.486–0.740], p < 0.0001]; ≥24 months: HR 0.352 [0.289–0.431], p < 0.0001).
Efficacy of real life results in using oral 5-ASA products for maintaining mild to moderate UC patients was favorable. Maintaining remission for 12 months or longer after induction therapy was shown to reduce recurrence risk thereafter.
Japan Intractable Diseases Information Center home page. http://www.nanbyou.or.jp/entry/62 Assessed 15 April 2013.
Ministry of Health, Labour and Welfare: Shared Study Report FY 2014 on “Research on intractable inflammatory bowel disease” (Suzuki Group), p. 383
Wang Y, Parker CE, Feagan BG, MacDonald JK. Oral 5-Aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2016;9:CD000544.
Ministry of Health, Labour and Welfare: Comprehensive Report of Shared Study FY2009 on “Research on intractable inflammatory bowel disease” (Watanabe Group), pp. 484–488
Cochran WG. Some methods of strengthening the common x2 tests. Biometrics. 1954;10:417–51. http://www,sciepub.com/reference/82589. CrossRef
Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48. PubMed
Ministry of Health, Labour and Welfare: Report on Public Health Administration and Services FY2012. ‘Specified intractable diseases. Number of possessor of certification of medical care for specified intractable diseases.’ http://www.mhlw.go.jp/toukei/saikin.
Ministry of Health, Labour and Welfare: Document on Tabulation of Personal Health Records FY. 2007.
Kawakami A, Tanaka M, Nishigaki M, Naganuma M, Iwao Y, Hibi T, et al. Relationship between non-adherence to aminosalicylate medication and the risk of clinical relapse among Japanese patients with ulcerative colitis in clinical remission: a prospective cohort study. J Gastroenterol. 2013;48:1006–15. CrossRefPubMed
- Real life results in using 5-ASA for maintaining mild to moderate UC patients in Japan, a multi-center study, OPTIMUM Study
OPTIMUM Study Group
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II